Reducing coronary heart disease associated with type 2 diabetes: Lifestyle intervention and treatment of dyslipidaemia

Diabetes Research and Clinical Practice

Volumn 61, Issue SUPPL. 1, 2003, Pages

  Tuomilehto, Jaakko ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Coronary heart disease; Diabetes; Dyslipdaemia; LDL cholesterol; Statin treatment

Indexed keywords

FENOFIBRATE; GLUCOSE; HEMOGLOBIN A; METFORMIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

BODY BUILD; BODY WEIGHT; CLINICAL TRIAL; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; FINLAND; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PROPHYLAXIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 0042168932     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00125-6     Document Type: Conference Paper

References (23)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), J. Am. Med. Assoc. 285 (2001) 2486-2497.
2. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur. Heart J. 19:1998;1434-1503.
3. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diab. Care. 25:(Suppl. 1):2002;S50-S60.
4. Diabetes mellitus and exercise. Diab. Care. 25:(Suppl. 1):2002;S64-S68.
5. Jung R.T. Obesity as a disease. Br. Med. Bull. 53:1997;307-321.
6. Tuomilehto J., Lindström J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl. J. Med. 344:2001;1343-1350.
7. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl. J. Med. 346:2002;393-403.
8. Laakso M., Lehto S., Penttila I., Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 88:1993;1421-1430.
9. Turner R.C., Millns H., Neil H.A.W., et al. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br. Med. J. 316:1998;823-828.
10. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care. 24:2001;683-689.
11. Pyörälä K., Pedersen T.R., Kjekshus J., Faergemann O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diab. Care. 20:1997;614-620.
12. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335:1996;1001-1009.
13. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation. 102:2000;1893-1900.
14. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diab. Care. 21:1999;160-178.
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
16. Rubins H.B., Sander J.R., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl. J. Med. 341:1999;410-418.
17. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 103:2001;357-362.
18. Management of dyslipidemia in adults with diabetes. Diab. Care. 25:(Suppl. 1):2002;S74-S77.
19. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk. 8:2001;383-390.
20. Davidson M., Ma P., Stein E.A., Gotto A.J.M. Jr, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89:2002;268-275.
21. Schneck D.W., Knopp R.H., Ballantyne C.M., McPherson R., Chitra R.R., Simonson S.G. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol. 91:2003;33-41.
22. Durrington P., Hamann A., Tuomilehto J., Smith K., Kallend D. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetelogia. 44:(Suppl. 1):2001;A165.
23. Durrington P.N., Tuomilehto J., Hamann A., Southworth H., Pears J., Kallend D. Effects of rosuvastatin alone and in combination with fenofibrate on lipid subfractions in patients with type 2 diabetes: results at 24 weeks. Circulation. 104:(Suppl. 2):2001;II-177.